Clinical Practice Committee     2008 Comments to FDA regarding Guidance on PGx Data Submissions  (April 2008) Comments to FDA regarding Guidance on Definitions for PGx and Sample Coding Categories  (April 2008) Comments to NIGMS regarding barriers to PGx research  (April 2008) Comments to NACB regarding Guidelines for Lab Analysis and Application of PGx to Clinical Practice  (March 2008) Comments to EMEA regarding Guidance on Definitions for PGx and Sample Coding Categories  (March 2008)   2007 Comments to FDA regarding Guidance for Industry and FDA Staff: Assayed and Unassayed Quality Control Material (Docket 98D-1232) (October 2007) Comments to FDA regarding Guidance for Industry and FDA Staff: Pharmacogenetic Tests and Genetic Tests for Heritable Markers (Docket 2006D-0012) (October 2007)   Response to The FMR1 Premutation and Premature Ovarian Failure: Worldwide Community Guideline Development (May 2007) Comments to the CDC Proficiency Testing Work Group (March 2007) AMP Response to HHS RFI regarding EHR (Jan 2007) Laboratory Staffing and Resources - Survey Results  (Feb. 2002) Connexin 26 Working Group  (Feb. 2002)

Professional Relations Committee 2008 Suggestions to the SACGHS regarding New Priorities (April 2008) Verbal Comments to the SACGHS Regarding Oversight of Genetic Testing Draft Report (February 2008) 2007 Comments to the SACGHS Task Force Draft Report Regarding Oversight of Genetic Testing (December 2007) AMP Position regarding Direct Access Genetic Testing (Direct to Consumer Genetic Testing) (June 2007) Letter to Sen. Dodd endorsing the "Medical Education Affordability Act"  (March 2007) Comments to the SACGHS (March 2007) Response to FDA regarding IVDMIA Draft Guidance document (March 2007) Response to FDA regarding ASR Draft Guidance document (March 2007) Comments to CLIAC regarding introducing a Genetics Specialty to the CLIA regulations (Feb 2007) Letter to the House and Senate supporting the Genetics Information Nondiscrimination Act (GINA) (January 2007)     >>2006 and Earlier

05/01/2008